BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Report 2024 and update on financial calendar

29 Apr 2025 22:03 CEST

Bergen, Norway - 29 April 2025- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announces that the Board of Directors today approved the
2024 Annual Financial Statements prepared in accordance with International
Financial Reporting Standards (IFRS).

The Annual Report for 2024 in pdf and European Single Electronic Format (ESEF)
are attached to this release and are also available on BerGenBio ASA's website
https://www.bergenbio.com/investors/reports/

Due to the ongoing strategic review and the cost savings initiative previously
announced, the board of directors has decided to only publish half yearly
financial reports. The board has also decided to delay the Annual General
Meeting to 26 June 2025. The finance calendar will be updated according to this.

Contacts:

Olav Hellebø CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer. BerGenBio is based in Bergen, Norway with
a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

644782_BerGenBio_ASA_Annual_report_2024.pdf
644782_213800TYYFXKYF3V2A23_2024_12_31_0_en.zip